QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文 JOURNAL OF HEPATOLOGY, 2019, 卷号: 70 作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun 收藏  |  浏览/下载：58/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05 THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang 收藏  |  浏览/下载：37/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05 THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang 收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05 Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model 期刊论文 BMC CANCER, 2019, 卷号: 19, 期号: 1 作者:  Wang, Lu;  Liu, Liyuan;  Lou, Zhen;  Ding, Lijie;  Guan, Hui 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/11 Breast neoplasms  Population at risk  Risk assessment   Valuing Guaranteed Minimum Death Benefits by Cosine Series Expansion 期刊论文 MATHEMATICS, 2019, 卷号: 7, 期号: 9 作者:  Yu, Wenguang;  Yong, Yaodi;  Guan, Guofeng;  Huang, Yujuan;  Su, Wen 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/11 equity-linked death benefits  Fourier cosine series expansion  guaranteed minimum death benefit  option  valuation  Levy process